Breaking News, Promotions & Moves

Pfizer Names Andrew Baum Chief Strategy and Innovation Officer, EVP

Baum brings 30 years of experience leading high-impact research projects and teams, developing robust strategies and forging global partnerships.

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer Inc. has named Andrew Baum, M.D., as Chief Strategy and Innovation Officer, Executive Vice President. Dr. Baum will be a member of Pfizer’s Executive Leadership Team reporting to Chairman and Chief Executive Officer, Dr. Albert Bourla. He joins the company from Citi, where he served as Head of Global Healthcare, Managing Director Equity Research. Prior to joining Citi in 2011, Dr. Baum covered European Pharmaceuticals at Morgan Stanley for 14 years and earlier in his career was a practicing physician at the Royal National Orthopaedic Radcliffe Hospital in Oxford where he completed his residency.

Dr. Baum will be responsible for portfolio analysis and prioritization functions, business development activities, strengthening partnerships with the biotech ecosystem, and the commercial evaluation of the research pipeline. In his role, he will also Chair Pfizer’s Portfolio Management Team responsible for capital deployment across the company’s research and development pipeline. Dr. Baum will begin his role at Pfizer on June 3, 2024, succeeding Aamir Malik, who recently moved into a new role at Pfizer as Chief U.S. Commercial Officer, Executive Vice President.

“Dr. Baum has a rare profile that combines deep clinical and scientific knowledge with strong financial expertise in fields such as equity research, hedge funds, investment banking and shareholder value creation strategies. As a former experienced analyst who followed Pfizer for over a decade, he will bring fresh strategic insights into the company’s business and portfolio,” said Dr. Albert Bourla, Chairman and Chief Executive Officer, Pfizer.

“I am thrilled to be joining Pfizer as Chief Strategy and Innovation Officer. I look forward to leveraging my prior experience to help Pfizer identify, accelerate and deliver more breakthrough therapies with the power to transform patients’ lives,” said Andrew Baum, M.D. “Pfizer is well placed to accelerate its growth given its deep current expertise in small molecules, antibody engineering and innovative vaccines.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters